Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens. - Wikidata - wikimedia - TriplyDB

Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.

Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.

http://www.wikidata.org/entity/Q37174100

about

Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: study of antibiotic combinations Emergence and management of drug-resistant enterococcal infections.Newer developments in the treatment of Gram-positive infections.Oritavancin, a new lipoglycopeptide antibiotic: results from a thorough QT study.Novel antibiotics for the treatment of Staphylococcus aureus.Assessment of oritavancin serum protein binding across species.Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.

P2860

Q37144883-19C1B74F-DC64-46FD-A6DC-0EFEBE717BB3 Q37291346-2142A897-FEF9-46BA-8579-5D49E9A1411C Q37636151-3C822C4F-1695-4FA2-992C-1A2F37529A67 Q38485341-34BFAC5D-7925-4D66-A1C8-5B30B686346D Q39933945-7F87163D-9A5E-4B00-9213-32F0FD3F62A1 Q42076292-96DC3F4E-AE5E-4638-BDB7-11FCD85EFF09 Q42111507-C87C0733-BEB7-46EB-A5B1-A110DBA976AF

P2860

Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.

http://www.wikidata.org/entity/Q37174100

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.

@en

Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.

@nl

type

label

Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.

@en

Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.

@nl

prefLabel

Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.

@en

Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.

@nl

P1433

Q37174100-8F212B0D-15BC-4E70-AC28-300AD99EADEF

P1476

Q37174100-27A796C9-D104-441C-AC86-AAF905F9C3DA

P2093

Q37174100-A20D0B15-6B12-4A80-BB04-BE1E95135082

Q37174100-A6C363DC-FCE0-4778-9F85-D440DDD982D3

P2860

Q37174100-069C02BD-7AD6-4F74-BACA-97E7A1151A23

Q37174100-06B929AB-3011-427B-B885-38D9CCC869B4

Q37174100-1092B425-B853-434E-90E3-AB5E587F54F5

Q37174100-1A189980-EA46-471A-8D7A-72A676AD0A1C

Q37174100-1B3D0D41-D9ED-4471-892E-CE89DDE974F2

Q37174100-1B6487AC-6533-42EF-BB94-7C7689603E64

Q37174100-1E011149-CAB9-422D-8B70-710A5BC9BE6B

Q37174100-25BE34B2-CCBC-4099-BB66-8FCBF20E80C7

Q37174100-39B38B97-60EB-4F88-917D-B0FC4C5F0A6D

Q37174100-40AFC5A8-E7FC-4E91-B80B-EA766E5150F6

P304

Q37174100-259BFE70-8549-4D0B-BA61-E046E632DA52

P31

Q37174100-BB0D0406-77ED-4A3A-969E-979B0E0F8B6A

P356

Q37174100-0C5044C7-0058-4A71-B6B1-329FE88850E2

P433

Q37174100-7D941647-715D-4F28-A102-F53135DAA3CE

P478

Q37174100-5842AC13-FC2F-402F-B41C-A0DF4C4CB608

P577

Q37174100-24D77AD1-2D69-4810-B4A4-7FB1859617E9

P698

Q37174100-98E8A16E-EC61-4D6A-BDC3-2019C4C63362

P921

Q37174100-93F88CD7-C0B0-4B0A-86DD-3E535D8B7E9A

P356

17460913.3.3.251

P1433

Future Microbiology

P1476

Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.

@en

P2093

David P Nicolau

http://www.w3.org/2001/XMLSchema#string

Jared Crandon

http://www.w3.org/2001/XMLSchema#string

P2860

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose.

Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model

Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis

Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation

Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.

Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.

Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center.

Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia.

Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection

P304

251-263

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/17460913.3.3.251

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18505390

http://www.w3.org/2001/XMLSchema#string

P921

Gram-positive bacteria